

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab (anti-PD-1)	[Red bar]			R/R cHL
	[Dark blue bar]			R/R cHL
BGB-10188 +/- Tislelizumab	[Blue bar]			B-cell malignancies
BGB-10188 (PI3K δ inhibitor) +/- Zanubrutinib (BTK Inhibitor)	[Blue bar]			B-cell lymphoid malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy	[Blue bar]			Mature B-cell malignancies
Zandelisib (PI3K δ inhibitor) +/- Zanubrutinib or Rituximab*	[Purple bar]			CLL/SLL and B-cell NHL
Zanubrutinib	[Dark blue bar]			R/R CLL/SLL
	[Dark blue bar]			1L and R/R WM
	[Dark blue bar]			R/R MZL
	[Teal bar]			Previously treated B-cell lymphoid malignancies
	[Pink bar]			B-cell lymphoid malignancies
Zanubrutinib + Lenalidomide +/- Rituximab	[Red bar]			R/R DLBCL
Zanubrutinib + Obinutuzumab	[Dark blue bar]			R/R FL
Zanubrutinib + Rituximab	[Dark blue bar]			1L MCL
Zanubrutinib +/- Venetoclax†	[Dark blue bar]			1L CLL/SLL

*In collaboration with MEI Pharma.
 †This combination is being studied in the third cohort of NCT03336333.

cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; R/R, recurrent/refractory; WM, Waldenström macroglobulinemia.

No BeiGene products are currently approved in the EU.

